Clinical Trial Update: Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) [Phase 3]

View source ↗

Summary

A Phase 3 single-dose trial of canakinumab in active systemic juvenile idiopathic arthritis was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Systemic Juvenile Idiopathic Arthritis | Phase 3 | Status: TERMINATED | Results posted: 2012-04-09